Your browser is no longer supported. Please, upgrade your browser.
Settings
LJPC La Jolla Pharmaceutical Company daily Stock Chart
LJPC [NASD]
La Jolla Pharmaceutical Company
Index- P/E- EPS (ttm)-2.89 Insider Own0.60% Shs Outstand27.33M Perf Week-18.68%
Market Cap105.06M Forward P/E- EPS next Y-1.33 Insider Trans- Shs Float26.96M Perf Month-9.24%
Income-78.60M PEG- EPS next Q-0.54 Inst Own87.60% Short Float12.85% Perf Quarter-18.16%
Sales26.40M P/S3.98 EPS this Y45.20% Inst Trans5.83% Short Ratio6.83 Perf Half Y-22.78%
Book/sh-2.90 P/B- EPS next Y28.50% ROA-62.00% Target Price- Perf Year-59.68%
Cash/sh2.61 P/C1.47 EPS next 5Y13.20% ROE129.00% 52W Range2.30 - 10.31 Perf YTD-2.54%
Dividend- P/FCF- EPS past 5Y-16.60% ROI183.30% 52W High-62.83% Beta2.45
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin89.10% 52W Low66.52% ATR0.34
Employees90 Current Ratio4.40 Sales Q/Q1.80% Oper. Margin- RSI (14)42.80 Volatility8.17% 7.72%
OptionableYes Debt/Eq- EPS Q/Q49.10% Profit Margin- Rel Volume1.04 Prev Close4.00
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout- Avg Volume507.18K Price3.83
Recom2.30 SMA20-8.96% SMA50-7.05% SMA200-29.15% Volume533,161 Change-4.25%
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral
Nov-25-19Downgrade SunTrust Buy → Hold
Jan-23-19Upgrade JP Morgan Underweight → Neutral
Jan-14-19Upgrade Jefferies Underperform → Hold
Feb-12-18Downgrade Jefferies Buy → Underperform
Jan-25-18Reiterated Chardan Capital Markets Neutral $90 → $100
Dec-26-17Reiterated SunTrust Buy $57 → $65
Dec-22-17Reiterated SunTrust Buy $67 → $65
Dec-22-17Reiterated H.C. Wainwright Buy $62 → $91
Dec-21-17Initiated H.C. Wainwright Buy $62
Dec-08-17Downgrade JP Morgan Overweight → Underweight
Aug-30-17Initiated JP Morgan Overweight $36
Feb-27-17Reiterated SunTrust Buy $38 → $57
Jun-22-16Initiated SunTrust Buy $30
May-24-16Initiated Lake Street Buy $25
Sep-08-15Reiterated Chardan Capital Markets Buy $60 → $80
Jul-07-15Reiterated Chardan Capital Markets Buy $54 → $60
May-11-15Reiterated H.C. Wainwright Buy $29 → $20
Apr-21-15Initiated Oppenheimer Outperform $43
Mar-20-15Reiterated H.C. Wainwright Buy $20 → $29
Aug-25-20 08:31AM  
Aug-21-20 02:02PM  
Aug-06-20 08:30AM  
Jul-28-20 04:16PM  
04:15PM  
Jun-24-20 07:30AM  
Jun-22-20 12:14PM  
Jun-14-20 07:00AM  
Jun-10-20 04:22PM  
May-21-20 08:30AM  
May-07-20 12:55PM  
May-06-20 08:41AM  
May-04-20 09:55AM  
08:30AM  
Apr-27-20 12:31PM  
Apr-13-20 08:30AM  
Apr-07-20 08:30AM  
Apr-06-20 08:30AM  
Apr-03-20 08:30AM  
Apr-02-20 08:30AM  
Mar-13-20 08:00AM  
Mar-02-20 09:55AM  
08:30AM  
Feb-24-20 12:30PM  
Jan-27-20 08:23AM  
Jan-18-20 05:09PM  
Jan-15-20 07:00AM  
Jan-09-20 08:00AM  
Dec-13-19 03:07PM  
Nov-26-19 08:06AM  
Nov-25-19 09:04AM  
08:35AM  
08:30AM  
Nov-15-19 09:52AM  
Nov-12-19 06:35PM  
04:47PM  
12:21PM  
Nov-11-19 09:59AM  
Oct-16-19 10:32AM  
Aug-29-19 09:00AM  
Aug-16-19 02:38PM  
Aug-14-19 03:36PM  
Aug-01-19 09:35AM  
08:00AM  
Jul-30-19 11:53AM  
11:31AM  
Jul-23-19 09:00AM  
Jul-01-19 08:39AM  
Jun-28-19 06:30AM  
Jun-11-19 11:55AM  
Jun-07-19 02:02PM  
Jun-06-19 09:00AM  
May-22-19 01:49PM  
May-06-19 06:25PM  
05:15PM  
04:11PM  
May-02-19 10:33AM  
Apr-29-19 01:25PM  
Apr-24-19 09:00AM  
Mar-11-19 07:30AM  
Mar-08-19 02:49PM  
Mar-07-19 04:01PM  
01:05PM  
Mar-06-19 08:56AM  
Mar-05-19 07:24AM  
Mar-04-19 06:33PM  
04:01PM  
Feb-25-19 04:04PM  
Feb-14-19 07:18PM  
Feb-05-19 08:20AM  
Jan-18-19 07:00AM  
Jan-10-19 07:00AM  
Jan-09-19 11:28AM  
Jan-07-19 10:25PM  
02:36PM  
12:55PM  
09:00AM  
Jan-04-19 09:00AM  
Dec-22-18 01:38AM  
Nov-06-18 08:35AM  
Oct-31-18 12:04PM  
Oct-25-18 03:55PM  
Oct-24-18 06:10PM  
05:06PM  
04:01PM  
07:48AM  
Oct-18-18 04:01PM  
Oct-16-18 11:21AM  
07:25AM  
Aug-16-18 08:00AM  
Aug-13-18 03:35PM  
Aug-09-18 12:51PM  
Aug-08-18 08:00PM  
06:55PM  
04:01PM  
02:30PM  
Aug-03-18 09:00AM  
Aug-01-18 05:39PM  
Jul-16-18 07:05AM  
Jun-25-18 09:00AM  
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN CDirectorSep 09Buy4.03126,665509,9409,405,490Sep 09 06:55 PM
RAMSAY DAVID ADirectorSep 08Buy3.831,0003,83048,000Sep 10 04:02 PM
TANG KEVIN CDirectorSep 08Buy3.9084,152328,5299,278,825Sep 09 06:55 PM
TANG KEVIN CDirectorSep 04Buy3.8267,552258,3599,194,673Sep 09 06:55 PM
RAMSAY DAVID ADirectorAug 24Buy3.767,00026,28947,000Aug 24 04:22 PM
RAMSAY DAVID ADirectorAug 21Buy3.9728,000111,10840,000Aug 24 04:22 PM
RAMSAY DAVID ADirectorAug 20Buy4.1712,00050,06012,000Aug 24 04:22 PM
TANG KEVIN CDirectorAug 14Buy3.88168,669653,6949,127,121Aug 14 04:49 PM
TANG KEVIN CDirectorAug 13Buy3.65219,465800,5868,958,452Aug 14 04:49 PM
TANG KEVIN CDirectorAug 12Buy3.4743,513150,8208,738,987Aug 14 04:49 PM
TANG KEVIN CDirectorJun 04Buy4.94215,8121,065,6368,695,474Jun 04 06:26 PM
TANG KEVIN CDirectorJun 03Buy4.90145,764714,7838,479,662Jun 04 06:26 PM
TANG KEVIN CDirectorJun 02Buy4.88253,5531,237,0608,333,898Jun 04 06:26 PM
TANG KEVIN CDirectorFeb 03Buy6.8075,003509,8338,080,345Feb 03 05:02 PM
TANG KEVIN CDirectorJan 31Buy6.7513,29289,7058,005,342Feb 03 05:02 PM
TANG KEVIN CDirectorJan 30Buy6.7281,475547,4317,992,050Feb 03 05:02 PM
Wellinghoff DarrylChief Commercial OfficerJan 14Buy8.233,00024,6776,545Jan 16 04:05 PM
TANG KEVIN CDirectorJan 13Buy6.661,253,8788,351,5807,910,575Jan 13 05:59 PM
TANG KEVIN CDirectorJan 10Buy5.70717,8044,090,9096,656,697Jan 13 05:59 PM
TANG KEVIN CDirectorJan 09Buy4.991,000,0004,991,9805,938,893Jan 13 05:59 PM
HRTX Heron Therapeutics, Inc. daily Stock Chart
HRTX [NASD]
Heron Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own0.13% Shs Outstand90.75M Perf Week-10.23%
Market Cap1.32B Forward P/E- EPS next Y-1.64 Insider Trans-0.97% Shs Float90.74M Perf Month-0.95%
Income-198.30M PEG- EPS next Q-0.63 Inst Own99.00% Short Float16.87% Perf Quarter-29.07%
Sales125.80M P/S10.49 EPS this Y-2.50% Inst Trans-4.11% Short Ratio12.28 Perf Half Y21.52%
Book/sh3.57 P/B4.08 EPS next Y33.60% ROA-43.60% Target Price- Perf Year-23.96%
Cash/sh3.32 P/C4.39 EPS next 5Y47.50% ROE-57.50% 52W Range9.60 - 26.81 Perf YTD-38.00%
Dividend- P/FCF- EPS past 5Y2.70% ROI-51.50% 52W High-45.65% Beta1.57
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin59.40% 52W Low51.77% ATR0.74
Employees231 Current Ratio4.20 Sales Q/Q-38.10% Oper. Margin- RSI (14)43.77 Volatility4.85% 5.14%
OptionableYes Debt/Eq0.02 EPS Q/Q3.70% Profit Margin- Rel Volume0.55 Prev Close14.80
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.25M Price14.57
Recom1.60 SMA20-1.62% SMA50-7.08% SMA200-17.33% Volume691,040 Change-1.55%
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jan-03-18Initiated Leerink Partners Outperform $22
Sep-27-17Initiated Northland Capital Outperform $40
Feb-27-17Initiated Needham Buy $28
Oct-26-16Initiated Aegis Capital Buy
Sep-06-16Resumed Lake Street Buy $45
May-03-16Initiated Cantor Fitzgerald Buy
Dec-10-15Initiated Lake Street Buy $45
Sep-23-15Reiterated Leerink Partners Outperform $38 → $57
Sep-02-15Initiated BofA/Merrill Buy $46
Aug-03-15Reiterated Brean Capital Buy $40 → $45
Jun-30-15Reiterated JMP Securities Mkt Outperform $25 → $33
Jun-19-15Reiterated Leerink Partners Outperform $26 → $38
Aug-07-14Initiated Noble Financial Buy $18
Sep-16-20 08:30AM  
Sep-11-20 04:05PM  
Sep-09-20 10:19AM  
Sep-08-20 08:30AM  
Aug-29-20 10:23AM  
Aug-12-20 01:00AM  
Aug-05-20 06:35PM  
Aug-04-20 11:26AM  
Jul-27-20 12:31PM  
Jul-24-20 10:29AM  
Jul-16-20 08:30AM  
Jul-02-20 10:38PM  
Jul-01-20 02:26PM  
Jun-30-20 11:15AM  
Jun-29-20 08:47AM  
08:45AM  
Jun-26-20 08:28AM  
Jun-23-20 07:51PM  
Jun-21-20 02:53PM  
Jun-16-20 10:00AM  
Jun-04-20 09:00AM  
May-20-20 10:04AM  
May-18-20 09:00AM  
May-09-20 08:00AM  
May-08-20 10:04AM  
May-06-20 10:35AM  
09:00AM  
May-05-20 07:31AM  
Apr-19-20 07:02AM  
Apr-09-20 04:05PM  
Apr-07-20 03:33PM  
Apr-05-20 09:57AM  
Mar-02-20 09:05AM  
07:30AM  
Feb-27-20 01:19PM  
08:42AM  
Feb-26-20 04:42PM  
Feb-21-20 12:30PM  
Feb-20-20 07:06AM  
Feb-19-20 06:16PM  
Feb-18-20 04:05PM  
Jan-27-20 11:01AM  
Jan-22-20 08:53AM  
Jan-13-20 08:30AM  
Dec-21-19 08:27AM  
Dec-16-19 04:05PM  
Dec-12-19 01:44PM  
Dec-10-19 05:18AM  
Dec-06-19 08:00AM  
Dec-03-19 07:30AM  
Nov-26-19 04:05PM  
Nov-25-19 09:13AM  
Nov-22-19 03:22PM  
Nov-15-19 09:00AM  
08:24AM  
Nov-14-19 04:05PM  
Nov-13-19 04:05PM  
Nov-12-19 09:45AM  
08:30AM  
Nov-11-19 01:59PM  
Oct-30-19 10:33AM  
05:15AM  
Oct-28-19 09:08AM  
08:30AM  
Oct-22-19 08:30AM  
Oct-07-19 12:14PM  
Oct-04-19 10:00PM  
06:10AM  
Oct-03-19 10:37PM  
04:01PM  
09:42AM  
Oct-02-19 12:23PM  
07:45AM  
Oct-01-19 04:10PM  
04:05PM  
08:30AM  
Sep-25-19 04:05PM  
Sep-04-19 10:00AM  
Aug-30-19 06:14PM  
Aug-29-19 07:31AM  
Aug-20-19 08:30AM  
Aug-06-19 03:40PM  
Aug-05-19 03:30PM  
03:00PM  
02:18PM  
10:45AM  
10:30AM  
09:45AM  
08:30AM  
08:15AM  
Aug-02-19 03:30PM  
03:00PM  
09:43AM  
07:10AM  
Aug-01-19 04:00PM  
02:46PM  
Jul-31-19 02:00PM  
12:53PM  
11:15AM  
10:29AM  
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MANHARD KIMBERLYExecutive VP, Drug DevelopmentMay 01Sale13.971,15816,1760May 01 06:48 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 29Option Exercise13.0024,000312,00024,000Dec 03 06:30 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 29Sale26.0024,000624,0000Dec 03 06:30 PM
TANG KEVIN CDirectorOct 04Buy17.50285,7144,999,9955,799,810Oct 07 05:18 PM
Quart Barry DChief Executive OfficerOct 03Buy17.504,57179,99394,652Oct 04 07:58 PM
POYHONEN JOHNEVP, Chief Commercial OfficerOct 03Buy17.505,14390,00318,143Oct 04 07:56 PM
ODT Odonate Therapeutics, Inc. daily Stock Chart
ODT [NASD]
Odonate Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.87 Insider Own1.70% Shs Outstand30.68M Perf Week-11.98%
Market Cap492.31M Forward P/E- EPS next Y-3.66 Insider Trans- Shs Float13.83M Perf Month-25.71%
Income-118.10M PEG- EPS next Q-0.93 Inst Own80.70% Short Float11.17% Perf Quarter-69.55%
Sales- P/S- EPS this Y-11.30% Inst Trans0.51% Short Ratio4.06 Perf Half Y-53.00%
Book/sh3.44 P/B3.78 EPS next Y6.90% ROA-67.80% Target Price- Perf Year-53.10%
Cash/sh3.31 P/C3.93 EPS next 5Y- ROE-80.10% 52W Range13.82 - 46.50 Perf YTD-59.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.04% Beta-
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low-5.93% ATR1.59
Employees134 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)21.82 Volatility6.03% 8.28%
OptionableYes Debt/Eq0.00 EPS Q/Q5.50% Profit Margin- Rel Volume1.73 Prev Close14.51
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume380.91K Price13.00
Recom2.20 SMA20-15.82% SMA50-53.28% SMA200-57.22% Volume646,723 Change-10.41%
Sep-24-20 03:43PM  
02:15PM  
01:35PM  
01:00PM  
06:20AM  
Sep-23-20 11:15PM  
07:26PM  
06:00PM  
01:45PM  
01:00PM  
11:30AM  
10:58AM  
Sep-22-20 02:15PM  
01:44PM  
10:00AM  
09:00AM  
06:20AM  
Sep-21-20 08:45PM  
08:30PM  
07:45PM  
04:55PM  
03:39PM  
02:45PM  
01:35PM  
01:00PM  
Sep-20-20 10:25AM  
Sep-19-20 10:07PM  
01:50PM  
Sep-18-20 10:00PM  
07:15PM  
05:08PM  
02:55PM  
02:19PM  
01:30PM  
12:40PM  
11:55AM  
11:00AM  
09:53AM  
Sep-17-20 02:54PM  
01:00PM  
11:40AM  
Sep-16-20 09:18PM  
01:20PM  
Sep-10-20 05:40PM  
Sep-08-20 10:30PM  
Sep-06-20 09:41PM  
Sep-04-20 06:11PM  
Sep-03-20 03:39PM  
Sep-01-20 11:30AM  
Aug-28-20 11:41AM  
Aug-27-20 07:45PM  
Aug-26-20 04:02PM  
03:44PM  
12:00AM  
Aug-25-20 10:55PM  
Aug-24-20 03:46PM  
07:30AM  
Aug-06-20 11:11AM  
Jul-30-20 08:15AM  
Jun-30-20 11:15PM  
May-29-20 08:30AM  
May-13-20 10:04AM  
Apr-28-20 08:15AM  
Apr-11-20 09:52AM  
Mar-25-20 07:49AM  
Feb-20-20 08:15AM  
Feb-11-20 09:30AM  
Dec-12-19 03:16PM  
Dec-11-19 09:47AM  
Dec-10-19 11:08AM  
Nov-06-19 08:20AM  
Oct-28-19 02:14PM  
Oct-21-19 08:30AM  
Sep-30-19 11:17AM  
Sep-27-19 09:51AM  
Jul-24-19 08:15AM  
Jul-09-19 08:34AM  
Jun-30-19 11:46PM  
Jun-28-19 07:15PM  
Jun-26-19 08:30AM  
Jun-25-19 04:01PM  
Jun-24-19 11:41AM  
Jun-18-19 11:15PM  
Jun-17-19 11:27AM  
Jun-10-19 09:15PM  
11:59AM  
Jun-03-19 09:00AM  
May-29-19 09:00AM  
May-08-19 08:01AM  
May-06-19 08:11AM  
Apr-25-19 08:15AM  
Apr-02-19 08:05AM  
Mar-28-19 08:30AM  
Mar-17-19 03:51PM  
Mar-14-19 10:18AM  
Mar-11-19 07:15PM  
Mar-06-19 04:30PM  
Mar-04-19 04:30PM  
Feb-28-19 08:30AM  
Feb-22-19 08:15AM  
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boxer Capital, LLCDirectorSep 09Buy15.2081,1001,232,7204,991,886Sep 09 05:59 PM
Davis Aaron I.DirectorSep 09Buy15.2081,1001,232,7204,991,886Sep 09 05:59 PM
Davis Aaron I.DirectorSep 08Buy14.6918,800276,1724,910,786Sep 09 05:59 PM
Boxer Capital, LLCDirectorSep 08Buy14.6918,800276,1724,910,786Sep 09 05:59 PM
Boxer Capital, LLCDirectorSep 04Buy14.89125,1001,862,7394,891,986Sep 09 05:59 PM
Davis Aaron I.DirectorSep 04Buy14.89125,1001,862,7394,891,986Sep 09 05:59 PM
Davis Aaron I.DirectorAug 28Buy14.251,403,50920,000,0034,766,886Sep 01 04:30 PM
Boxer Capital, LLCDirectorAug 28Buy14.251,403,50920,000,0034,766,886Sep 01 04:30 PM
TANG KEVIN CChief Executive OfficerAug 28Buy14.251,052,63114,999,99215,127,900Sep 01 08:17 AM